If you have been reading about Tetrapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC | Reported as percent area, often ≥95% |
| Identity confirmation | Mass spectrometry | Observed mass compared with ~390 Da |
| Typical storage temperature | -20 °C or below | Lyophilized powder, desiccated |
| Reconstitution solvent | Sterile water or buffer | Acidic residues aid dissolution |
| Common synonyms | AEDG; epithalon | Spelling varies in literature |
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
== Functional features == Observations of limiting enzymatic hydrolysis elicited by trypsin in a controlled environment have shown an increase in hemp protein isolate (HSI) solubility at various pH and a notable decrease in the recorded emulsifying activity index.
{\displaystyle {\begin{aligned}u(y,z)&={\frac {G}{2\mu }}(y+z)(\pi -y)-{\frac {G}{\pi \mu }}\sum _{n=1}^{\infty }{\frac {1}{\beta _{n}^{3}\sinh(2\pi \beta _{n})}}\left\{\sinh[\beta _{n}(2\pi -y+z)]\sin[\beta _{n}(y+z)]-\sinh[\beta _{n}(y+z)]\sin[\beta _{n}(y-z)]\right\},\quad \beta _{n}=n+{\tfrac {1}{2}},\\[6pt]Q&={\frac {G\pi ^{4}}{12\mu }}-{\frac {G}{2\pi \mu }}\sum _{n=1}^{\infty }{\frac {1}{\beta _{n}^{5}}}\left[\coth(2\pi \beta _{n})+\csc(2\pi \beta _{n})\right].\end{aligned}}}
Drugs can also be transferred through the skin (transdermal). Inhalers are also of interest, as for example, asthma drugs consist of macromolecules. Currently, the inhalation systems are undesirable to patients, and it is hoped that there will be advances in this delivery system at some time.
== Leadership == The director is Dr. Charles Peloquin who has been leading this facility for over 20 years. This facility is unique in that it provides finely detailed interpretations of results as applied to adjusting the drug regimens of individual patients. Dr. Peloquin's research efforts focuses on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.
Sources: en.wikipedia.org
Due to globin defects, beta thalassemia patients do not have normal levels of adult hemoglobin (HbA), and instead have elevated levels of HbA2 (α2δ2). Production of this form of hemoglobin may increase as a consequence of stress erythropoiesis.
== Awards and affiliations == Smith a principal investigator at NIH Biomedical Technology Resource Center for Integrative Biology and the U.S. Department of Energy High Throughput Proteomics Facility at PNNL. He is an adjunct faculty member in the chemistry departments at Washington State University and the University of Utah and an affiliate faculty member Department of Chemistry at the University of Idaho and the Department of Molecular Microbiology & Immunology, Oregon Health & Science University. Smith serves on the Board of Scientific Counselors, Office of Public Health Preparedness and Response of the Centers for Disease Control and Prevention. He is also a Fellow of the American Association for the Advancement of Science, and has been elected to the Washington State Academy of Sciences. In 2011, Discover Magazine selected a peer-reviewed paper on Lyme disease that he coauthored with immunologist Steven Schutzer of the University of Medicine and Dentistry of New Jersey as one of the top 100 articles of the year, placing it at number 90. He was the recipient of the 2003 ACS award in Analytical Chemistry, the 2009 Human Proteome Organization (HUPO) Discovery Award in Proteomics Sciences, and was selected by R&D Magazine as the 2010 R&D Scientist of the Year.
Beginning in the 1950s, Knoxville made serious efforts to reinvigorate the downtown area. One of the city's first major renovation efforts involved the replacement of the large Market House on Market Square with a pedestrian mall. The city also made numerous attempts to lure shoppers back to Gay Street, starting with the Downtown Promenade in 1960, in which walkways were constructed behind buildings along the street's eastern half, and continuing with the so-called "Gay Way," which included the widening of sidewalks and the installation of storefront canopies, in 1964. Downtown retailers continued to slip, however, and with the completion of West Town Mall in 1972, the downtown retail market collapsed. Miller's, Kress's, and the three surviving downtown theaters had all closed by 1978. In 1962, Knoxville annexed several large communities, namely Fountain City and Inskip north of the city, and Bearden and West Hills west of the city. This brought large numbers of progressive voters into the city, diluting the influence of Cas Walker and his allies. In the early 1970s, Mayor Kyle Testerman, backed by a more open city council, implemented the "1990 Plan," which essentially abandoned attempts to lure large retailers back to the downtown area, aiming instead to create a financial district accompanied by neighborhoods containing a mixture of residences, office space, and specialty shops. In 1978, Knoxville and Knox County voters again voted on the issue of metropolitan government. In spite of support by U.T.
Sources: en.wikipedia.org
Identity is normally confirmed by mass spectrometry, which checks the measured mass against the expected value near 390 daltons. Reverse-phase high-performance liquid chromatography is used alongside it to assess purity. Amino acid analysis can provide additional composition data.
The powder is generally kept refrigerated or frozen, protected from light and moisture. Vials should reach room temperature before opening to prevent condensation. Reconstituted solutions are usually stored cold and used within a limited window because dilute solutions can degrade or support microbial growth.
Epitalon is not an approved drug in major Western regulatory jurisdictions. Its legal status differs between countries, and it is often distributed as a research chemical. This means product documentation and purity vary considerably between suppliers.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.